Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Abcellera Biologics Inc stock

Learn how to easily invest in Abcellera Biologics Inc stock.

AbCellera Biologics Inc. completed its initial public offering and its shares are now available on the Nasdaq under "ABCL." Vancouver-based AbCellera is an AI-powered drug discovery company working with Eli Lilly & Co. on a COVID-19 vaccine.

How to buy shares in Abcellera Biologics Inc

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ABCL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Abcellera Biologics Inc stock price (NASDAQ: ABCL)

Use our graph to track the performance of ABCL stocks over time.

Abcellera Biologics Inc shares at a glance

Information last updated 2022-07-01.
Latest market close$10.64
52-week range$5.42 - $22.63
50-day moving average $8.26
200-day moving average $11.64
Wall St. target price$30.00
PE ratio 16.625
Dividend yield $0 (0%)
Earnings per share (TTM) $0.64

Buy Abcellera Biologics Inc shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Abcellera Biologics Inc stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Abcellera Biologics Inc price performance over time

Historical closes compared with the close of $10.64 from 2022-07-01

1 week (2022-06-28) 3.70%
1 month (2022-06-01) 36.41%
3 months (2022-04-05) 5.77%
6 months (2022-01-05) -13.21%
1 year (2021-07-02) -48.05%
2 years (2020-07-01) N/A
3 years (2019-07-01) N/A
5 years (2017-07-01) N/A

Is Abcellera Biologics Inc stock undervalued or overvalued?

Valuing Abcellera Biologics Inc stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Abcellera Biologics Inc's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Abcellera Biologics Inc's P/E ratio

Abcellera Biologics Inc's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 17x. In other words, Abcellera Biologics Inc shares trade at around 17x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, Abcellera Biologics Inc's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

Abcellera Biologics Inc's EBITDA

Abcellera Biologics Inc's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $286.4 million.

The EBITDA is a measure of a Abcellera Biologics Inc's overall financial performance and is widely used to measure a its profitability.

To put Abcellera Biologics Inc's EBITDA into context you can compare it against that of similar companies.

Abcellera Biologics Inc financials

Revenue TTM $489 million
Operating margin TTM 55.47%
Gross profit TTM $267.6 million
Return on assets TTM 12.46%
Return on equity TTM 18.92%
Profit margin 41.88%
Book value $4.24
Market capitalisation $3 billion

TTM: trailing 12 months

Abcellera Biologics Inc share dividends

We're not expecting Abcellera Biologics Inc to pay a dividend over the next 12 months.

Abcellera Biologics Inc overview

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Frequently asked questions

What percentage of Abcellera Biologics Inc is owned by insiders or institutions?
Currently 28.823% of Abcellera Biologics Inc shares are held by insiders and 40.319% by institutions.
How many people work for Abcellera Biologics Inc?
Latest data suggests 400 work at Abcellera Biologics Inc.
When does the fiscal year end for Abcellera Biologics Inc?
Abcellera Biologics Inc's fiscal year ends in December.
Where is Abcellera Biologics Inc based?
Abcellera Biologics Inc's address is: 2215 Yukon Street, Vancouver, BC, Canada, V5Y 0A1
What is Abcellera Biologics Inc's ISIN number?
Abcellera Biologics Inc's international securities identification number is: CA00288U1066

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site